

Market Announcement

17 July 2020

Rhythm Biosciences Limited (ASX: RHY) – Trading Halt (2+2)

Description

The securities of Rhythm Biosciences Limited ('RHY') will be placed in trading halt at the request of RHY, pending it releasing an announcement regarding a capital raising. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 23 July 2020 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)

Request for Trading Halt

17 July 2020

Melissa Kostopoulos
Listing Compliance - Melbourne
ASX Compliance Pty Ltd
525 Collins Street
North Tower Level 4
MELBOURNE VIC 3000

Dear Melissa

Pursuant to ASX Listing Rule 17.1, Rhythm Biosciences Limited ACN 619 459 335 (Company) requests that the ASX grants two (2) consecutive trading halts with respect to the Company's shares.

The trading halt(s) are requested pending an announcement to be made by the Company to the market in connection with considering, planning and executing a material capital raising ("purpose").

In accordance with Listing Rule 17.1, the Company provides the following information in relation to the request:

1. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make a material announcement to the market for the stated purpose.
2. The Company requests that the trading halt remains in place until the earlier of commencement of normal trading on Thursday 23 July 2020, or when the announcement regarding the purpose is released to the market.
3. The Company expects to make the announcement to the market before the commencement of normal trading on Thursday 23 July 2020.
4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

Please contact me if you require any further information concerning this matter.

Released with the authority of the Board.

Yours sincerely



Mr Adrien Wing
Company Secretary

Rhythm Biosciences

ACN: 619 459 335
ASX: RHY

Issued Capital

100,750,000 Shares
3,000,000 Options

Australian Registered Office

Level 17, 500 Collins Street
Melbourne VIC 3000
www.rhythmbio.com

Directors

Otto Buttula – Chairman of the Board
Trevor John Lockett – Executive Director
Louis James Panaccio – Non-Executive Director
David John White – Non-Executive Director
Eduardo Vom – Non-Executive Director